Chongqing Lummy Pharmaceutical (300006) — Net Asset Quality Index
Chongqing Lummy Pharmaceutical (300006) has a Net Asset Quality Index of 67.0% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.76 Billion minus total liabilities of CN¥910.32 Million yields net assets of CN¥1.85 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See defensive interval ratio of Chongqing Lummy Pharmaceutical to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Chongqing Lummy Pharmaceutical Net Asset Quality Index Over Time (2006–2024)
This chart shows how Chongqing Lummy Pharmaceutical's Net Asset Quality Index has evolved across 19 annual periods from 2006 to 2024. As of September 2025, the index stands at 67.0%, representing net assets of CN¥1.85 Billion against total assets of CN¥2.76 Billion CNY. Explore cash efficiency ratio of Chongqing Lummy Pharmaceutical to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Chongqing Lummy Pharmaceutical (2006–2024)
The table below presents the year-by-year Net Asset Quality Index for Chongqing Lummy Pharmaceutical from 2006 to 2024, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Chongqing Lummy Pharmaceutical (300006) market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 65.9% | CN¥1.88 Billion | CN¥2.86 Billion | CN¥972.47 Million | ▼ -7.5 pp |
| 2023 | 73.4% | CN¥2.12 Billion | CN¥2.89 Billion | CN¥768.71 Million | ▲ +1.9 pp |
| 2022 | 71.5% | CN¥2.18 Billion | CN¥3.05 Billion | CN¥870.02 Million | ▼ -4.1 pp |
| 2021 | 75.6% | CN¥2.21 Billion | CN¥2.93 Billion | CN¥714.65 Million | ▲ +36.5 pp |
| 2020 | 39.1% | CN¥1.23 Billion | CN¥3.15 Billion | CN¥1.92 Billion | ▼ -8.1 pp |
| 2019 | 47.2% | CN¥1.65 Billion | CN¥3.50 Billion | CN¥1.85 Billion | ▼ -7.7 pp |
| 2018 | 54.9% | CN¥1.72 Billion | CN¥3.14 Billion | CN¥1.42 Billion | ▼ -8.0 pp |
| 2017 | 62.9% | CN¥1.72 Billion | CN¥2.74 Billion | CN¥1.02 Billion | ▼ -4.5 pp |
| 2016 | 67.4% | CN¥1.67 Billion | CN¥2.48 Billion | CN¥809.85 Million | ▲ +12.9 pp |
| 2015 | 54.5% | CN¥1.69 Billion | CN¥3.10 Billion | CN¥1.41 Billion | ▲ +9.1 pp |
| 2014 | 45.3% | CN¥1.02 Billion | CN¥2.24 Billion | CN¥1.23 Billion | ▼ -6.3 pp |
| 2013 | 51.6% | CN¥1.13 Billion | CN¥2.18 Billion | CN¥1.06 Billion | ▲ +1.7 pp |
| 2012 | 49.9% | CN¥710.51 Million | CN¥1.42 Billion | CN¥713.21 Million | ▼ -11.2 pp |
| 2011 | 61.1% | CN¥660.17 Million | CN¥1.08 Billion | CN¥420.81 Million | ▼ -2.5 pp |
| 2010 | 63.5% | CN¥561.59 Million | CN¥884.01 Million | CN¥322.42 Million | ▼ -16.8 pp |
| 2009 | 80.3% | CN¥525.08 Million | CN¥653.63 Million | CN¥128.55 Million | ▲ +29.0 pp |
| 2008 | 51.3% | CN¥137.79 Million | CN¥268.56 Million | CN¥130.77 Million | ▲ +1.0 pp |
| 2007 | 50.3% | CN¥107.91 Million | CN¥214.69 Million | CN¥106.78 Million | ▼ -1.2 pp |
| 2006 | 51.5% | CN¥64.39 Million | CN¥125.10 Million | CN¥60.72 Million | — |